Exploring the Cucurbitacin E (CuE) as an Anti-Lung Cancer Lead Compound through Molecular Docking, ADMET, Pass Prediction and Drug Likeness Analysis
DOI:
https://doi.org/10.26538/tjnpr/v8i2.24Keywords:
Drug likeness, PASS prediction, ADMET study, Molecular docking, Anti-lung cancer, Cucurbitacin E.Abstract
Cucurbitacin E (CuE) is a potent bioactive compound derived from the family of cucurbitaceae. CuE has recently been demonstrated to have outstanding potential to inhibit the growth of different kinds of cancer cells. CuE has been proven to have a strong anticancer effect on lung cancer in different in vitro and in vivo studies up to this date. In the present study, molecular docking of CuE was performed against three major proteins respectively myosin 9b [5C5S (Chain: A, B, C, D)], epidermal growth factor receptor (EGFRK) [1M17 (Chain: A)] and yes-associated protein (YAP) [3KYS (Chain: A, C)] associated with lung cancer. Different types of computers based softwires like GaussView 6.0, Gabedit, Swiss-PDB, Pymol, PyRx (Version 0.8), Discover Studio (2021) etc. are used for computational study. On the other hand, for developing the pharmacokinetic profile of the drug several online servers like Drug bank online, Pub Chem, RCSB:PDB, Webmo server, Online smile convertor, ADMET prediction, PASS prediction, Drug likeness analysis etc. are used. The molecular docking results showed that CuE possessed the best ligand protein interaction with 5C5S (Chain: A) protein where the binding score was -9.1 kJ/mol. Moreover, the non-bonding interactions ensure the significant binding affinity of CuE with 5C5S (Chain: A) protein to show antineoplastic effect against lung cancer. However, the present study reveals that CuE is the potent anti-lung cancer lead compound confirmed by the ligand protein interactions, ADMET calculation, PASS prediction and drug likeness analysis. Therefore, this study may be helpful towards the research community to think CuE as the best antineoplastic agent for treating lung cancer.
References
Abbas Z, Rehman S. An Overview of Cancer Treatment Modalities. In: Neoplasm. In Tech, 2018.
Madani SY, Naderi N, Dissanayake O, Tan A, Seifalian AM. A new era of cancer treatment: carbon nanotubes as drug delivery tools. Int J Nanomedicine. 2011;6:2963–2979.
Sharma R. Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050. Int J Clin Oncol 2022;27(4):665–675.
Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, Petrella F, Spaggiari L, Rosell R. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015 May 21;1:15009.
Abacioglu U, Yumuk PF, Caglar H, Sengoz M, Turhal NS. Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer. BMC Cancer 2005;5.
Yang CS, Li G, Yang Z, Guan F, Chen A, Ju J. Cancer prevention by tocopherols and tea polyphenols. Cancer Lett. 2013;334(1):79–85.
Khan N, Mukhtar H. Dietary agents for prevention and treatment of lung cancer. Cancer Lett. 2015;359(2):155–164.
Li X, Yang G, Li X, Zhang Y, Yang J, Chang J, Sun X, Zhou X, Guo Y, Xu Y, Liu J, Bensoussan A. Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in chinese. PLoS One. 2013;8(4):e60338.
Jian CC, Ming HC, Rui LN, Cordel GA, Qiuz SX. Cucurbitacins and cucurbitane glycosides: Structures and biological activities. Nat Prod Rep. 2005;22(3):386–399.
Duncun KLK, Duncun MD, Alley MC, Suusville’ EA. Cucurbitacin E-Induced Disruption of the Actin and Vimentin Cytoskeleton in Prdstate Carcinoma Cells. 1996.
Tuli HS, Rath P, Chauhan A, Ranjan A, Ramniwas S, Sak K, Aggarwal D, Kumar M, Dhama K, Lee EHC, Yap KC, Capinpin SM, Kumar AP. Cucurbitacins as Potent Chemo-Preventive Agents: Mechanistic Insight and Recent Trends. Biomolecules. 2022;13(1):57.
Debnath P, Das B, Singha S, Kar A, Haldar PK, Sharma N, Mukherjee PK. Quantification of cucurbitacin E in different varieties of melon (Cucumis melo L.) fruit through validated RP-HPLC method. Nat Prod Res. 2022; 24:1-7.
Ma G, Luo W, Lu J, Ma DL, Leung CH, Wang Y, Chen X. Cucurbitacin E induces caspase-dependent apoptosis and protective autophagy mediated by ROS in lung cancer cells. Chem Biol Interact. 2016 Jun 25;253:1-9.
Si-Yuan J, Zi-Dan W, Tie-Hua Z, Jie Z, Zheng-Yi W. In vitro antitumor effect of cucurbitacin E on human lung cancer cell line and its molecular mechanism. Available from: www.sciencedirect.com
Hsu PC, Tian B, Yang YL, Wang YC, Liu S, Urisman A, Yang CT, Xu Z, Jablons DM, You L. Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model. Oncol Rep. 2019 Aug;42(2):697-707.
Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, Li Q, Shoemaker BA, Thiessen PA, Yu B, Zaslavsky L, Zhang J, Bolton EE. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2021 Jan 8;49(D1):D1388-D1395.
Burley SK, Bhikadiya C, Bi C, Bittrich S, Chen L, Crichlow GV, Christie CH, Dalenberg K, Di Costanzo L, Duarte JM, Dutta S, Feng Z, Ganesan S, Goodsell DS, Ghosh S, Green RK, Guranović V, Guzenko D, Hudson BP, Lawson CL, Liang Y, Lowe R, Namkoong H, Peisach E, Persikova I, Randle C, Rose A, Rose Y, Sali A, Segura J, Sekharan M, Shao C, Tao YP, Voigt M, Westbrook JD, Young JY, Zardecki C, Zhuravleva M. RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences. Nucleic Acids Res. 2021;49(D1):D437-D451.
Seeliger D, Groot BL De. Conformational transitions upon ligand binding: Holo-structure prediction from apo conformations. PLoS Comput Biol 2010;6(1).
Morris GM, Lim-Wilby M. Molecular Docking [Homepage on the Internet]. Available from: http://www.biosolveit.de/FlexX
Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Methods in Molecular Biology 2015;1263:243–250.
Cheng F, Li W, Zhou Y, Shen J, Wu Z, Liu G, Lee PW, Tang Y. admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model. 2012; 52(11):3099-105.
Pogodin P V., Lagunin AA, Filimonov DA, Poroikov V V. PASS Targets: Ligand-based multi-target computational system based on a public data and naïve Bayes approach. SAR QSAR Environ Res 2015;26(10):783–793.
Mohammed Matin AM, Roshid MH, Bhattacharjee SC, KMS Azad A. PASS Predication, Antiviral, in vitro Antimicrobial, and ADMET Studies of Rhamnopyranoside Esters [Homepage on the Internet]. 2020; Available from: http://www.pharmaexpert.ru/
Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017;7.
Abdullahi SH, Uzairu A, Ibrahim MT, Umar AB. Chemo-informatics activity prediction, ligand based drug design, Molecular docking and pharmacokinetics studies of some series of 4, 6-diaryl-2-pyrimidinamine derivatives as anti-cancer agents. Bull Natl Res Cent 2021;45(1).
Flores-Holguín N, Frau J, Glossman-Mitnik D. Computational Pharmacokinetics Report, ADMET Study and Conceptual DFT-Based Estimation of the Chemical Reactivity Properties of Marine Cyclopeptides. ChemistryOpen 2021;10(11):1142–1149.
Adelusi TI, Abdul-Hammed M, Idris MO, Kehinde OQ, Boyenle ID, Divine UC, Adedotun IO, Folorunsho AA, Kolawole OE. Exploring the inhibitory potentials of Momordica charantia bioactive compounds against Keap1-Kelch protein using computational approaches. In Silico Pharmacol. 2021 Jun 25;9(1):39.
Wang Z, Hop ECA, Leung KH, Pang J. Determination of in vitro permeability of drug candidates through a Caco-2 cell monolayer by liquid chromatography/tandem mass spectrometry. 2000;
Breemen RB Van, Li Y. Caco-2 cell permeability assays to measure drug absorption. Expert Opin Drug Metab Toxicol. 2005;1(2):175–185.
Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 2015;58(9):4066–4072.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2012;64(SUPPL.):4–17.
Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 2002;45(12):2615–2623.
Mbarik M, Poirier SJ, Doiron J, Selka A, Barnett DA, Cormier M, Touaibia M, Surette ME. Phenolic acid phenethylesters and their corresponding ketones: Inhibition of 5-lipoxygenase and stability in human blood and HepaRG cells. Pharmacol Res Perspect. 2019 Sep 13;7(5):e00524
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Tropical Journal of Natural Product Research (TJNPR)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
